Pro-Pharmaceuticals, Inc. (PRW) Collaborates with Numoda Corporation to Manage Phase III Clinical Trial to Increase Speed-to-Market for DAVANAT(R)  
9/13/2010 9:50:56 AM

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has engaged the Numoda Corporation, a leading information, process and logistics management company, to oversee the Phase III clinical trial of DAVANATĀ® and 5-FU compared with the standard of care in the treatment of patients with advanced, metastatic colorectal cancer.